Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed

Lung Cancer

Volumn 74, Issue 1, 2011, Pages 132-138

  Chen, Chung Yu ^a   Chang, Yih Leong ^a   Shih, Jin Yuan ^a   Lin, Jou Wei ^a   Chen, Kuan Yu ^a   Yang, Chih Hsin ^a   Yu, Chong Jen ^a   Yang, Pan Chyr ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Adenocarcinoma; Dihydrofolate reductase; Non small cell lung cancer; Pemetrexed; Thymidylate synthase

Indexed keywords

DIHYDROFOLATE REDUCTASE; PEMETREXED; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER CHEMOTHERAPY; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; TETRAHYDROFOLATE DEHYDROGENASE; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 80052554890     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.01.024     Document Type: Article

References (40)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
2. SEER cancer statistics review, 1975-2005 2008, National Cancer Institute, Bethesda, MD. L.A.G. Ries, D. Melbert, M. Krapcho, D.G. Stinchcomb, N. Howlader, M.J. Horner, A. Mariotto, B.A. Miller, E.J. Feuer, S.F. Altekruse, D.R. Lewis, L. Clegg, M.P. Eisner, M. Reichman, B.K. Edwards (Eds.).
3. Non-small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995, 311:899-908.
4. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker S., Olak J., Stover D., Strawn J.R., Turrisi A.T., Somerfield M.R. American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22:330-353.
5. Azzoli C.G., Baker S., Temin S., Pao W., Aliff T., Brahmer J., Johnson D.H., Laskin J.L., Masters G., Milton D., Nordquist L., Pfister D.G., Piantadosi S., Schiller J.H., Smith R., Smith T.J., Strawn J.R., Trent D., Giaccone G. American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
6. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
7. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
8. Solomon B., Bunn PA Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent. Future Oncol 2005, 1:733-746.
9. Joerger M., Omlin A., Cerny T., Früh M. The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Curr Drug Targets 2010, 11:37-47.
10. Wu M.F., Hsiao Y.M., Huang C.F., Huang Y.H., Yang W.J., Chan H.W., Chang J.T., Ko J.L. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells. J Thorac Oncol 2010, 5:1143-1151.
11. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 1997, 111:1710-1717.
12. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., Van Glabbeke M., van Oosterom A.T., Christian M.C., Gwyther S.G. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
13. Righi L., Papotti M.G., Ceppi P., Billè A., Bacillo E., Molinaro L., Ruffini E., Scagliotti G.V., Selvaggi G. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 2010, 28:1534-1539.
14. Lenz H.J., Leichman C.G., Danenberg K.D. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1995, 14:176-182.
15. Yamachika T., Nakanishi H., Inada K., Tsukamoto T., Kato T., Fukushima M., Inoue M., Tatematsu M. A new prognostic factor for colorectal carcinoma, thymidylate synthase and its therapeutic significance. Cancer 1998, 82:70-77.
16. Karlberg M., Ohrling K., Edler D., Hallström M., Ullén H., Ragnhammar P. Prognostic and predictive value of thymidylate synthase expression in primary colorectal cancer. Anticancer Res 2010, 30:645-651.
17. Qiu L.X., Tang Q.Y., Bai J.L., Qian X.P., Li R.T., Liu B.R., Zheng M.H. Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: evidence from 24 studies. Int J Cancer 2008, 123:2384-2389.
18. Shintani Y., Ohta M., Hirabayashi H., Tanaka H., Iuchi K., Nakagawa K., Maeda H., Kido T., Miyoshi S., Matsuda H. New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int J Cancer 2003, 104:790-795.
19. Nakagawa T., Tanaka F., Otake Y., Yanagihara K., Miyahara R., Matsuoka K., Takata T., Yamada T., Fukushima M., Wada H. Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung. Lung Cancer 2002, 35:165-170.
20. Huang C., Liu D., Masuya D., Nakashima T., Kameyama K., Ishikawa S., Ueno M., Haba R., Yokomise H. Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer 2005, 92:1231-1239.
21. Huang C.L., Yokomise H., Kobayashi S., Fukushima M., Hitomi S., Wada H. Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. Int J Oncol 2000, 17:47-54.
22. Miyoshi T., Kondo K., Toba H., Yoshida M., Fujino H., Kenzaki K., Sakiyama S., Takehisa M., Tangoku A. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer. Anticancer Res 2007, 27:2641-2648.
23. Chang M.H., Ahn J.S., Lee J., Kim K.H., Park Y.H., Han J., Ahn M.J., Park K. The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. Lung Cancer 2010, 69:323-329.
24. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., Gatzemeier U., Tsao T.C., Pless M., Muller T., Lim H.L., Desch C., Szondy K., Gervais R., Shaharyar, Manegold C., Paul S., Paoletti P., Einhorn L., Bunn P.A. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
25. Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Peterson P., Simms L., Shepherd F.A. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009, 14:253-263.
26. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., Serwatowski P., Gatzemeier U., Digumarti R., Zukin M., Lee J.S., Mellemgaard A., Park K., Patil S., Rolski J., Goksel T., de Marinis F., Simms L., Sugarman K.P., Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
27. Ceppi P., Volante M., Saviozzi S., Rapa I., Novello S., Cambieri A., Lo Iacono M., Cappia S., Papotti M., Scagliotti G.V. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006, 107:1589-1596.
28. Gandara D.R., Grimminger P.P., Mack P.C., Danenberg P.V., Lara P., Danenberg K.D. Histology- and gender-related associations of ERCC1 RRM1, and TS biomarkers in 1802 patients with NSCLC: implications for therapy. J Clin Oncol (meeting abstracts) 2010, 28:7513.
29. Giovannetti E., Mey V., Nannizzi S., Pasqualetti G., Marini L., Del Tacca M., Danesi R. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non small-cell lung cancer cells. Mol Pharmacol 2005, 68:110-118.
30. Giovannetti E., Lemos C., Tekle C., Smid K., Nannizzi S., Rodriguez J.A., Ricciardi S., Danesi R., Giaccone G., Peters G.J. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol 2008, 73:1290-1300.
31. Sigmond J., Backus H.H., Wouters D., Temmink O.H., Jansen G., Peters G.J. Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 2003, 66:431-438.
32. Chen M.J., Shimada T., Moulton A.D., Cline A., Humphries R.K., Maizel J., Nienhuis A.W. The functional human dihydrofolate reductase gene. J Biol Chem 1984, 259:3933-3943.
33. Bertino J.R. Cancer research: from folate antagonism to molecular targets. Best Pract Res Clin Haematol 2009, 22:577-582.
34. Banerjee D., Ercikan-Abali E., Waltham M., Schnieders B., Hochhauser D., Li W.W., Fan J., Gorlick R., Goker E., Bertino J.R. Molecular mechanisms of resistance to antifolates: a review. Acta Biochim Pol 1995, 42:457-464.
35. Banerjee D., Mayer-Kuckuk P., Capiaux G., Budak-Alpdogan T., Gorlick R., Bertino J.R. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta 2002, 1587:164-173.
36. McGuire J.J. Anticancer antifolates: current status and future directions. Curr Pharm Des 2003, 9:2593-2613.
37. Takemura Y., Kobayashi H., Miyachi H. Cellular and molecular mechanisms of resistance to antifolate drugs: new analogues and approaches to overcome the resistance. Int J Hemato. 1997, 66:459-477.
38. Shih C., Chen V.J., Gossett L.S., Gates S.B., MacKellar W.C., Habeck L.L., Shackelford K.A., Mendelsohn L.G., Soose D.J., Patel V.F., Andis S.L., Bewley J.R., Rayl E.A., Moroson B.A., Beardsley G.P., Kohler W., Ratnam M., Schultz R.M. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate requiring enzymes. Cancer Res 1997, 57:1116-1123.
39. Walling J. From methotrexate to pemetrexed and beyond: a review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs 2006, 24:37-77.
40. Uramoto H., Onitsuka T., Shimokawa H., Hanagiri T. TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed. Anticancer Res 2010, 4309-4315.